초록 ▼

Implantable or insertable medical devices are provided, which comprises: (a) a biocompatible polymer; and (b) at least one therapeutic agent selected from an anti-inflammatory agent, an analgesic agent, an anesthetic agent, and an antispasmodic agent. The medical devices are adapted for implantation

Implantable or insertable medical devices are provided, which comprises: (a) a biocompatible polymer; and (b) at least one therapeutic agent selected from an anti-inflammatory agent, an analgesic agent, an anesthetic agent, and an antispasmodic agent. The medical devices are adapted for implantation or insertion at a site associated with pain or discomfort upon implantation or insertion. In many embodiments, the therapeutic will be selected from at least one of (i) ketorolac and pharmaceutically acceptable salts thereof (e.g., ketorolac tromethamine) and (ii) 4-diethylamino-2-butynylphenylcyclohexyl glycolate and pharmaceutically acceptable salts thereof (e.g., oxybutynin chloride). Also provided are uses for the implantable or insertable medical devices, which uses comprise reducing pain or discomfort accompanying the implantation or insertion of such devices. Further uses may comprise reducing microbial buildup along the device. Methods for manufacturing implantable or insertable medical devices are also provided.

대표청구항 ▼

1. An implantable or insertable medical device comprising: a single-layer matrix polymer structure formed from a mixture comprising an extruded polymeric matrix region comprising (a) a biocompatible polymer, (b) a radio-opacifying agent, and (c) at least one therapeutic agent, wherein said medical d

1. An implantable or insertable medical device comprising: a single-layer matrix polymer structure formed from a mixture comprising an extruded polymeric matrix region comprising (a) a biocompatible polymer, (b) a radio-opacifying agent, and (c) at least one therapeutic agent, wherein said medical device is adapted for implantation or insertion at a site that is associated with pain or discomfort upon implantation or insertion, wherein said radio-opacifying agent is bismuth subcarbonate,wherein said therapeutic agent is ketorolac and pharmaceutically acceptable salts thereof, andwherein said biocompatible polymer is an ethylene-vinyl acetate (EVA) copolymer. 2. The implantable or insertable medical device of claim 1, wherein said medical device comprises (a) a first extruded polymeric matrix region comprising a first biocompatible polymer and said therapeutic agent, and (b) a second extruded polymer matrix region comprising a second biocompatible polymer and said radio-opacifying agent, wherein said first and second biocompatible polymers may be the same or different. 3. The implantable or insertable medical device of claim 1, wherein said extruded polymeric matrix region comprises 5-20% therapeutic agent. 4. The implantable or insertable medical device of claim 1, wherein said therapeutic agent is ketorolac tromethamine. 5. The implantable or insertable medical device of claim 1, wherein said extruded polymeric matrix region comprises 15-30% radio-opacifying agent. 6. The implantable or insertable medical device of claim 1, further comprising a barrier layer. 7. The implantable or insertable medical device of claim 1, further comprising an antimicrobial agent. 8. The implantable or insertable medical device of claim 1, further comprising a hydrogel. 9. The implantable or insertable medical device of claim 1, wherein the extruded polymeric matrix region comprises ethylene-vinyl acetate (EVA) copolymer, ketorolac tromethamine and bismuth subcarbonate. 10. The implantable or insertable medical device of claim 9, wherein the degradation level of the ketorolac tromethamine is less than 2%. 11. A method of manufacturing an implantable or insertable medical device that comprises a polymeric matrix region comprising: (a) a biocompatible polymer, (b) at least one therapeutic agent selected from ketorolac and pharmaceutically acceptable salts thereof and (c) a radio-opacifying agent, wherein said medical device is adapted for implantation or insertion at a site that is associated with pain or discomfort upon implantation or insertion, said method comprising: providing a combination comprising said biocompatible polymer, said therapeutic agent and said radio-opacifying agent;extruding said combination; andforming said polymeric matrix from said combination into a single-layer matrix polymer structure, wherein said radio-opacifying agent is bismuth subcarbonate, and wherein said biocompatible polymer is an ethylene-vinyl acetate (EVA) copolymer. 12. The method of claim 11, wherein forming said polymeric matrix comprises (a) forming an initial blend comprising said biocompatible polymer and said radio-opacifying agent; (b) combining said initial blend and said therapeutic agent; and (c) forming said polymeric matrix. 13. The method of claim 12, wherein said initial blend is formed using a thermoplastic process. 14. The method of claim 12, wherein said initial blend is formed using an extrusion process. 15. The method of claim 13, wherein said polymeric matrix is formed using a further thermoplastic process. 16. The method of claim 15, wherein said further thermoplastic process is conducted under conditions such that substantial degradation of said therapeutic agent is avoided. 17. The method of claim 15, wherein said further thermoplastic process is conducted under conditions such that degradation of said therapeutic agent is less than 2%. 18. The method of claim 12, wherein said initial blend is formed using a solution process. 19. The implantable or insertable medical device of claim 1, wherein the implantable or insertable medical device is a ureteral stent. 20. The method of claim 11, wherein the implantable or insertable medical device is a ureteral stent. 21. The implantable or insertable medical device of claim 9, wherein the implantable or insertable medical device is a ureteral stent. 22. The implantable or insertable medical device of claim 1, wherein said medical device is a ureteral stent and wherein the cumulative release of therapeutic agent is in an amount selected from 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, and 99%, relative to the total therapeutic agent in the device, after implantation or insertion at said site for a period selected from 1 day, 2 days, 4 days, 1 week, 2 weeks, 1 month, 2 months, 4 months, 1 year and 2 years. 23. The device of claim 1, further comprising a lubricious layer comprising one or more hydrogels comprising a hydrophilic polymeric material.